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The central event of each signaling
step in biology is biomolecular recogni-
tion. Notwithstanding the importance of
nucleic acids, carbohydrates, or lipids in
ligand-target interactions, the effectors
of most signal transduction processes are
peptides. These can be fragments of pro-
teins or stand-alone hormones, cytokines,
toxins, antimicrobials, and many other
types of peptides. At this point there is
no good reason to classify peptides by the
number of amino acid residues. We con-
sider peptides as any polyamide (or even
biopolymer with ester, thioester, or other-
wise modified backbone) that can be made
on a contemporary chemical peptide syn-
thesizer. The limit in size is greater than the
arbitrary cutoff of 50 amino acids set up
by the US Food and Drug Administration
(Carton and Strohl, 2013) for proteins and
far exceeds that of biological recognition
elements. While target recognition can
occur with as low as a few residues (Ertl
et al., 1991), even wide binding groves can
be bound by 30–40 residue long peptides.
Thus, in principle synthetic peptides can
be used to regulate almost all receptor
responses.
The high specificity and low toxic-
ity of peptide drugs derive from their
extremely tight binding to their targets.
This is due to the large chemical space
the side-chain variations of native amino
acids cover. Current databases estimate
the total number of valid protein-ligand
binding sites at 7700 (Khazanov and
Carlson, 2013). Calculation based on 17
variable residues (Cys, Met, and Trp are
significantly underrepresented in known
ligands), show that an 83,000-member
tetrapeptide library can be prepared that
will essentially cover all unique protein
binding regions. As the median length of
an active site is 11 amino-acid residues
(Khazanov and Carlson, 2013), designed
ligands should also be longer. While his-
torically six-residue positional scanning
could identify ligands of receptors or epi-
topes of monoclonal antibodies (Dooley
and Houghten, 1993), in our experience
receptor agonists are 9–12 residue long
(Otvos et al., 2008, 2011a)much likemajor
histocompatibility complex binding pep-
tides (Appella et al., 1995). Antagonists
acting on the same receptor binding sites
are somewhat shorter (vide infra). If it
is assumed that conformational prefer-
ences improve the binding kinetics but
only rarely thermodynamics, then the
tremendous specificity of side-chain com-
binations of peptides over six residues
in length can be even further expanded
by using non-natural residues. Hundreds
of appropriately protected and activated
non-natural amino acid derivatives, ready
for incorporation into synthetic pep-
tides, are commercially available and
indeed are frequently explored in peptide-
based drug design. Importantly, chemi-
cal biology has provided both backbone
and side-chain combinations for explor-
ing an enormous chemical space and
is expected to supply peptide chemists
with further building blocks suitable for
identifying close-to-ideal agonists and
antagonists of any biologically important
target.
The selectivity of peptide drugs for their
target is highlighted by the elevated suc-
cess rate in clinical trials. According to
a biotechnology report (Thomas, 2013),
of the 40 approved drugs in 2012, five
(12.5%) were peptides compared to 28
small molecule drugs and two mono-
clonal antibodies (in addition to three
enzymes, a cell-based drug and a vaccine).
However, in a recent report, the total num-
ber of peptide approvals between 2001
and 2012 was 19 (Kaspar and Reichert,
2013). Due to the low number of drug
approvals, any particularly successful year
can bias the ratios significantly. According
to another report, the overall success rate
of all drugs entering clinical trials is just
10.4% (Hay et al., 2014). Sixty-five percent
of small molecules proceed from Phase
I to Phase II in non-oncology applica-
tions, a figure identical for peptide/protein
drugs. Interestingly peptides/proteins out-
perform small molecules at the Phase
II → Phase III transition stage with
29% for small molecules and 42% for
the larger drug candidates. While pep-
tides have traditionally been considered
safe in Phase I clinical trials, the public
perception is that they are less benefi-
cial in late clinical trials when they are
compared side-by-side with different types
of treatment modalities. It must be men-
tioned that peptides are less successful
in oncology than in other applications.
The cost of large scale peptide produc-
tion might well-exceed those of small
molecule drugs, but if one considers the
total cost of the drug development pro-
cess, the active pharmaceutical ingredient
expense will remain under 3% (Otvos,
2014a). In direct opposition to concerns
with expensive peptides, the increased
clinical success rate, and thus, overall
expense/approved drug ratio compared to
small molecule chemical entities, make
peptide drug development particularly
attractive.
The biochemical processes that acti-
vated receptors directly or indirectly reg-
ulate include protein phosphorylation,
nucleic acid transcription, ion transport,
and a series of enzyme activities (Yan
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and Wang, 2012). Ligands (e.g., drugs,
hormones, neurotransmitters) bind to
receptors and ligand binding activates
or inactivates the target and accelerates
or inhibits given cellular functions. For
peptide-based drug development, a com-
promise has to be found between the
required peptide length and pharmaco-
logically useful levels of receptor acti-
vation. The numerous variables include
(i) the size and accessibility of ligand
binding surfaces, (ii) possible induced fit;
(iii) ligand stability and receptor resi-
dency time. Contemporary drug develop-
ment requires nano- or picomolar cellular
responses especially for receptor-mediated
biological processes. As an example, our
leptin receptor agonist peptides must
be at least 11 amino acid residues in
length (Otvos et al., 2008), similar to
other peptide hormone receptor activa-
tors (Demchyshyn et al., 2000; Shimizu
et al., 2001). For turning peptide ago-
nists into antagonists, the literature data
(Hruby, 2002; Sillerud and Larson, 2005)
support our own personal experience.
Truncation of the sequence or non-natural
amino acid replacement usually leads to
antagonist or inverse agonist derivatives.
Our nine-residue leptin receptor antago-
nist Allo-aca follows these design rules and
shows opposite effects to the agonist both
in vitro and in vivo (Otvos et al., 2011b).
Moreover, a library based on the agonist
or conformational restriction may allow
the selection of peptides with antagonist
properties.
In spite of all listed attractive features,
ongoing negative public opinion limits
more widespread acceptance of peptide
drugs. A major challenge in the com-
ing decade will be to modify peptide
(polyamide) sequences or properties to
overcome these valid concerns and to
educate the public to dismiss or reduce
the unfounded misconceptions. One of
the true drawbacks of peptide drugs is
the increased proteolytic instability com-
pared to not only small molecules but
also monoclonal antibody therapeutics.
The Fc fragment of monoclonal antibodies
reshuffle the protein to cells and peptide-
Fc conjugates may also be protected from
enzymatic cleavage (Boylan et al., 2013).
Chemically, both the amide bond and
the side-chains can be altered to render
the resulting peptidomimetics resistant to
proteolytic degradation (Gentilucci et al.,
2010). The serum stability assay provides
a ready measure of peptide stability and
was once considered the most significant
secondary screening tool in drug develop-
ment (Powell et al., 1992). Indeed, serum
stability can provide a strong prediction of
the all-important pharmacokinetic behav-
ior of drugs.
Nevertheless, the discord between the
pharmacokinetics (what the body does
to the drug) and the pharmacodynam-
ics (what the drug does to the body)
of peptide therapeutics warrants revisit-
ing the importance of stability per se. In a
mouse model of triple negative breast can-
cer, Allo-aca is more efficacious than any
other current therapy regimen as indicated
by survival figures (Otvos et al., 2011c).
Due to the similarity of molecular mech-
anisms in arthritis and cancer, Allo-aca
softens rheumatoid arthritis development
markers in mice indicating clear and long-
term activity of the peptide in vivo (Otvos
et al., 2011d). At the same time, Allo-
aca decomposes within 30min in human
serum and is undetectable in pharma-
cokinetic measurements 1 h after subcuta-
neous administration (Otvos et al., 2014).
The remarkable in vivo efficacies can be
explained by the dynamics of Allo-aca
binding to the leptin receptor. The esti-
mated binding affinity of biotin-labeled
Allo-aca to the ligand binding domain of
the receptor is 300 pM and the dissoci-
ation rate constant of 1.5 × 10-4/s cor-
responds to a peptide-receptor complex
half-life of nearly 2 h. Allo-aca, and other
peptide drugs excel in terms of high activ-
ity and target selectivity regardless of poor
serum stability and pharmacokinetics.
Peptide-based drugs may modify receptor
responses significantly longer than stan-
dard stability analyses indicate. Indeed,
Allo-aca produces weight gain in normal
mice even two days after a 0.1mg/kg bolus
subcutaneous administration despite the
very short-lived blood levels. In addi-
tion, because peptides are rapidly excreted
through the kidney, serum stability studies
are not representative of true turnover. The
5–10min Tmax of peptide drug leads in
mouse pharmacokinetics measurements is
significantly shorter than true serum pres-
ence in humans where the renal clearance
rate is 10-fold longer (Sakamoto et al.,
1993). Even if they are cleaved into smaller
fragments, peptidic metabolites frequently
retain the intended biological function
(Noto et al., 2008).
Improvement in peptide drug pene-
tration through biological barriers can
be achieved by adding modules for pas-
sive or active transport (Fasano, 1998).
Incorporation of positively charged amino
acids, especially at terminal positions
improves cell and tissue penetration of
peptides (Teesalu et al., 2009; Li and Cho,
2012). Repetitive arginine-containing
modules help even nuclear uptake in vitro
or bioavailability in vivo (Wender et al.,
2000). One problem is that polycations
frequently destroy mammalian mem-
branes as shown by the toxic properties of
natural or designer antibacterial peptides
that contain large numbers of lysines and
arginines (Cudic et al., 2002). Presumably,
a safer solution is to conjugate thera-
peutic peptides to ligands of cell surface
receptors. While absorptive-mediated
uptake features micromolar saturation
constants, generally receptor-mediated
uptake is characterized by Kd values in
the low nanomolar range. Cell surface
receptors that can be targeted for internal-
ization of peptides include carbohydrate
receptors, lipoprotein receptors, transfer-
ring receptors, and receptors involved in
cell adhesion. Perhaps the most widely
used of these is the incorporation of
various sugars to improve tissue pene-
tration, including the transport across the
blood-brain barrier. In the first exam-
ple, coupling a maltose moiety to the
N-terminus of a somatostatin octapep-
tide analog resulted in about 10-fold
increased oral bioavailability while main-
taining the selectivity and duration of
action of the original peptide (Albert
et al., 1993). Later this technology was
extended to increase in intraintestinal
absorption of vasopressin (Kihlberg et al.,
1995), the stability of peptide drugs and
brain transport of enkephalin analogs
(Egleton and Davis, 2005), and more
recently to simultaneous intestinal drug
absorption and blood-brain barrier pen-
etration of endomorphine-1, an opioid
tetrapeptide (Varamini et al., 2012). In
our experience, a leptin receptor ago-
nist glycopeptide E1/Aca reduces weight
gain in mice fed with high-fat peanut
diet in a dose-dependent manner, unlike
native leptin protein. In mice undergoing
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leptin glycopeptide treatment, several
obesity-related pathologies (i.e., abnormal
metabolic profile and liver histology as
well as infertility) are normalized while
unglycosylated leptin protein therapy
does not show similar positive treatment
outcomes (Kovalszky et al., 2010).
Another related area where chemical
biology can make critical contributions
is increasing the sensitivity of quanti-
tative analysis of peptides. The current
limit of quantitation of peptides in plasma
by using nano-high-performance liquid
chromatography assays is approximately
25 nM (Otvos et al., 2014), around the
lower limit of the 10 ng/mL dynamic range
(in a 10-mer peptide this is equivalent of
10 nM) in validated pharmaceutical pro-
tocols (Zannikos et al., 2000). However,
receptor agonist and antagonist peptide
drugs act in the pM range, and they are
present in mouse blood at a concentration
higher than the 100–500 pM IC50 value
well-beyond the 30–60min mark that cor-
responds to the limit of quantitation of the
analysis. The situation is less problematic
in humans where higher blood volumes
are available than in rodents, although the
required drug doses in humans are about
12-fold lower than in mice due to dif-
ferences in the body surface area/weight
ratio (Reagan-Shaw et al., 2008). Human
serum concentrations of triptorelin, a
10-residue agonist of the gonadotropin-
releasing hormone receptor, at 8 ng/mL are
already associated with activation of 90%
of the receptor population (Romero et al.,
2012). In turn, even if the sensitivity of
the murine plasma quantification proto-
col can be increased by a magnitude, later
time points will still be missed when highly
active peptide drugs are present in the
circulation above their IC50/EC50 figures.
Finally, oral bioavailability (in fact
the lack thereof) is a constant discus-
sion topic between peptide drug develop-
ers and pharma. Peptides can rarely be
absorbed by the intestinal mucosa, and
thus cannot serve the appealing lifestyle
drug market that includes treatments for
weight-loss, smoking, erectile dysfunction,
wrinkles, and baldness (Atkinson, 2002).
Much effort and monetary resources are
expended in the endeavor to make pep-
tides orally active. Chemical and physi-
cal modifications that can improve oral
bioavailability of peptide drugs include
conjugation to passive and active trans-
port enhancers (vide supra). In addition to
these covalent modification technologies,
micro- and nanoparticles further increase
peptide delivery options. In most cases,
as soon as a peptide drug lead is iden-
tified, research is initiated to improve
its oral availability. In the latest exam-
ple, mucoadhesive devices, made of car-
bopol, pectin and sodium methylcarboxy
cellulose, in enteric coated capsules sig-
nificantly improve the oral bioavailability
and pharmacodynamics parameters of an
existing peptide drug, salmon calcitonin
(Gupta et al., 2013).
However, it must be said that peptide
drugs do not necessarily need to be orally
available.Many peptide hormones, includ-
ing insulin, amylin, somatostatin, and
human growth hormone are now avail-
able in patient-friendly packaging ready
for subcutaneous self-administration.
The luteinizing hormone-releasing hor-
mone receptor agonist leuprolide, is
currently available in a once-a-year
implantable device for commercial use.
At a research scale, the transdermal deliv-
ery of leuprolide can be further improved
by using microneedles and/or iontophore-
sis (Sachdeva et al., 2013). Many peptides
can be formulated for intranasal admin-
istration, a technique that can utilize
olfactory neurons to bypass blood-brain
barrier restrictions for central nervous
system therapeutics (Charlton et al.,
2008). Unsurpassed intranasal efficacies
for peptides, comparable to those mea-
sured after injection, are also achieved by
using alkylsaccharide transmucosal deliv-
ery agents (Maggio, 2006). In fact the
market is saturated nowwith personalized,
reusable, and virtually painless transder-
mal or intranasal medical devices for drug
administration.
Taken together, the therapeutic poten-
tial of peptide-based drugs is increas-
ingly appreciated and their development
is both strong and growing rapidly.
At this juncture, the role of chemi-
cal biology is twofold: solve or improve
some of the suboptimal parameters of
peptides such as poor pharmacokinet-
ics or lack of oral activity simulta-
neously with educating biotechnology
investors and less informed commer-
cial drug developers about the miscon-
ceptions (immunogenicity, high price,
unfavorable pharmacodynamics, lack of
delivery options) that still linger over
peptide-based therapeutics and delay the
realization of the use of these highly
active and safe therapy options (Otvos,
2014b). By addressing these outstanding
issues, peptide-based drugs will finally be
accepted as genuine alternatives to tradi-
tional small molecule therapeutics.
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